Solventum Reports Third-Quarter Revenue of $1.95 Billion, Raises 2026 EPS Guidance
Solventum reported adjusted EPS of $1.45 and raised its full-year 2026 adjusted EPS guidance to $7.20–$7.30. Revenue and adjusted EPS exceeded FactSet estimates of $1.93 billion and $1.34, respectively.
Solventum Corporation announced its third-quarter 2026 financial results, reporting revenue of $1.95 billion, which surpassed the FactSet consensus estimate of $1.93 billion. The company posted an adjusted earnings per share (EPS) of $1.45, outperforming the analyst estimate of $1.34. Alongside these results, Solventum raised its full-year 2026 adjusted EPS guidance to a range of $7.20 to $7.30, compared to the FactSet estimate of $7.15. These figures reflect the company's performance as an independent healthcare entity following its spin-off from 3M.